Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies

Emmanuelle Weiller,1 Catherine Weiss,2 Christopher P Watling,3 Christopher Edge,3 Mary Hobart,2 Hans Eriksson,1 Maurizio Fava4–6 1H. Lundbeck A/S, Valby, Copenhagen, Denmark; 2Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA; 3Cambridge Medical Commun...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Weiller E, Weiss C, Watling CP, Edge C, Hobart M, Eriksson H, Fava M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Depression antidepressant adjunct Sheehan Disability Scale functional work Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/abdfed5f9cc94204b7f923f86fe3c5ef
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:abdfed5f9cc94204b7f923f86fe3c5ef
record_format	dspace
spelling	oai:doaj.org-article:abdfed5f9cc94204b7f923f86fe3c5ef2021-12-02T07:10:39ZFunctioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies1178-2021https://doaj.org/article/abdfed5f9cc94204b7f923f86fe3c5ef2017-12-01T00:00:00Zhttps://www.dovepress.com/functioning-outcomes--with-adjunctive-treatments-for-major-depressive--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Emmanuelle Weiller,1 Catherine Weiss,2 Christopher P Watling,3 Christopher Edge,3 Mary Hobart,2 Hans Eriksson,1 Maurizio Fava4–6 1H. Lundbeck A/S, Valby, Copenhagen, Denmark; 2Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA; 3Cambridge Medical Communication Ltd, Cambridge, UK; 4Division of Clinical Research of the MGH Research Institute, 5Department of Psychiatry, 6Clinical Trials Network & Institute (CTNI), Massachusetts General Hospital, Boston, MA, USA Objective: Patients with major depressive disorder (MDD) with inadequate response to antidepressant treatment (ADT) may suffer a prolonged loss of functioning. This review aimed to determine if self-rated functional measures are informative in randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. Methods: This was a systematic literature review of articles in any language from the MEDLINE database published between January 1990 and March 2017. Eligible studies met the following criteria: patients with MDD; inadequate response to at least one ADT; adjunctive therapy (pharmacological or otherwise) to ADT; placebo control group; randomized controlled trial or a post hoc analysis of a randomized controlled trial; reported a self-rated functioning scale. Study characteristics and functioning efficacy data were extracted. Results: A total of 2,090 discrete records were screened, 293 full-text articles were assessed for eligibility, and 26 studies were included. All studies were acute (6–12 weeks) except for one 52-week study. The only self-rated functioning scale used in the included studies was the Sheehan Disability Scale (SDS). Of the 13 adjunctive agents identified, aripiprazole, brexpiprazole, edivoxetine, and risperidone improved functioning versus placebo (p<0.05), as measured by the SDS total or mean score. On the SDS “work/studies” item, only aripiprazole had a statistically significant benefit, in one study out of four. Thus, where a benefit was observed on the SDS total or mean, this was generally driven by improvement on the “social life” and “family life” items. A limitation of the review is that it only considered published literature from one database. Conclusion: The SDS, a self-rated functional measure, is informative in acute randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. However, the item that measures work performance may be less relevant to this population than the items that measure social and family life. Keywords: depression, antidepressant, adjunct, Sheehan Disability Scale, functional, workWeiller EWeiss CWatling CPEdge CHobart MEriksson HFava MDove Medical PressarticleDepressionantidepressantadjunctSheehan Disability ScalefunctionalworkNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 103-115 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Depression antidepressant adjunct Sheehan Disability Scale functional work Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Depression antidepressant adjunct Sheehan Disability Scale functional work Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Weiller E Weiss C Watling CP Edge C Hobart M Eriksson H Fava M Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
description	Emmanuelle Weiller,1 Catherine Weiss,2 Christopher P Watling,3 Christopher Edge,3 Mary Hobart,2 Hans Eriksson,1 Maurizio Fava4–6 1H. Lundbeck A/S, Valby, Copenhagen, Denmark; 2Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA; 3Cambridge Medical Communication Ltd, Cambridge, UK; 4Division of Clinical Research of the MGH Research Institute, 5Department of Psychiatry, 6Clinical Trials Network & Institute (CTNI), Massachusetts General Hospital, Boston, MA, USA Objective: Patients with major depressive disorder (MDD) with inadequate response to antidepressant treatment (ADT) may suffer a prolonged loss of functioning. This review aimed to determine if self-rated functional measures are informative in randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. Methods: This was a systematic literature review of articles in any language from the MEDLINE database published between January 1990 and March 2017. Eligible studies met the following criteria: patients with MDD; inadequate response to at least one ADT; adjunctive therapy (pharmacological or otherwise) to ADT; placebo control group; randomized controlled trial or a post hoc analysis of a randomized controlled trial; reported a self-rated functioning scale. Study characteristics and functioning efficacy data were extracted. Results: A total of 2,090 discrete records were screened, 293 full-text articles were assessed for eligibility, and 26 studies were included. All studies were acute (6–12 weeks) except for one 52-week study. The only self-rated functioning scale used in the included studies was the Sheehan Disability Scale (SDS). Of the 13 adjunctive agents identified, aripiprazole, brexpiprazole, edivoxetine, and risperidone improved functioning versus placebo (p<0.05), as measured by the SDS total or mean score. On the SDS “work/studies” item, only aripiprazole had a statistically significant benefit, in one study out of four. Thus, where a benefit was observed on the SDS total or mean, this was generally driven by improvement on the “social life” and “family life” items. A limitation of the review is that it only considered published literature from one database. Conclusion: The SDS, a self-rated functional measure, is informative in acute randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. However, the item that measures work performance may be less relevant to this population than the items that measure social and family life. Keywords: depression, antidepressant, adjunct, Sheehan Disability Scale, functional, work
format	article
author	Weiller E Weiss C Watling CP Edge C Hobart M Eriksson H Fava M
author_facet	Weiller E Weiss C Watling CP Edge C Hobart M Eriksson H Fava M
author_sort	Weiller E
title	Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
title_short	Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
title_full	Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
title_fullStr	Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
title_full_unstemmed	Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
title_sort	functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/abdfed5f9cc94204b7f923f86fe3c5ef
work_keys_str_mv	AT weillere functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies AT weissc functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies AT watlingcp functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies AT edgec functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies AT hobartm functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies AT erikssonh functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies AT favam functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies
_version_	1718399594310664192

Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies

Ejemplares similares